Keiling R, Armand P P, Hurteloup P, Cappelaere P
Onkologie. 1986 Aug;9 Suppl 1:8-10. doi: 10.1159/000216054.
239 patients were evaluable: 116 in the FAC arm, 123 in the FEC arm. There is no significant difference in the therapeutic responses between 2 regimens: 52 +/- 9% vs 49 +/- 9%. Duration of responses (273 vs 303 d) and overall survival were also similar. FEC appears less myelotoxic, less toxic also in terms nausea, vomiting and grade 3 alopecia than the adriamycin combination. 9 patients required treatment cessation due to grade 2 cardiac dysfunction with 3 CHF, against no case in the epirubicin regimen.
239例患者可进行评估：氟尿嘧啶、多柔比星和顺铂（FAC）方案组116例，氟尿嘧啶、表柔比星和顺铂（FEC）方案组123例。两种方案的治疗反应无显著差异：分别为52±9%和49±9%。反应持续时间（分别为273天和303天）及总生存期也相似。FEC方案的骨髓毒性似乎较小，在恶心、呕吐及3级脱发方面的毒性也较小。9例患者因2级心脏功能障碍需要停止治疗，其中3例发生充血性心力衰竭（CHF），而表柔比星方案组无此情况。
